Sangamo Therapeutics Inc (NASDAQ: SGMO) Shares Are Heading Higher

Best AI Stocks

In the last trading session, 1.03 million shares of the Sangamo Therapeutics Inc (NASDAQ:SGMO) were traded, and its beta was 1.41. Most recently the company’s share price was $0.51, and it changed around $0.02 or 5.44% from the last close, which brings the market valuation of the company to $104.18M. SGMO currently trades at a discount to its 52-week high of $1.78, offering almost -249.02% off that amount. The share price’s 52-week low was $0.29, which indicates that the current value has risen by an impressive 43.14% since then. We note from Sangamo Therapeutics Inc’s average daily trading volume that its 3-month average coming to 2.39 million.

Sangamo Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.88. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended SGMO as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Sangamo Therapeutics Inc is expected to report earnings per share of $Silicon Motion Technology Corpo for the current quarter.

Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information

Instantly SGMO has showed a green trend with a performance of 5.44% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -5.85% year-to-date, but still down -5.87% over the last five days. On the other hand, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -37.32% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 95.75% from its current value. Analyst projections state that SGMO is forecast to be at a low of $5 and a high of $19.

Sangamo Therapeutics Inc (SGMO) estimates and forecasts

Sangamo Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -4.57 percent over the past six months and at a 8.47% annual growth rate that is well below the industry average of 13.30%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -15.96%.

SGMO Dividends

Sangamo Therapeutics Inc’s next quarterly earnings report is expected to be released in May.